Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

March 4, 2025 South African watchdog probes Novo Nordisk and Sanofi over insulin ... anti-competitive practices in the human insulin pen market, the authority said on Tuesday.

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...